headlinez.news Live news trend intelligence
↑ Rising Health

Studies: Blood test has potential to detect CTE in the living

A blood test measuring a specific tau fragment distinguished advanced CTE from early or absent disease in 21 brain donors, marking the first time a living biomarker has tracked autopsy-confirmed CTE stages.

8sources
8articles
28velocity
+102%since first seen
1h agofirst detected
Text:
⚡ TREND RADAR BRIEF Health · Rising
  • Intelligence Anchor: Studies: Blood test has potential to detect CTE in the living
  • Core Takeaway: A blood test measuring a specific tau fragment distinguished advanced CTE from early or absent disease in 21 brain donors, marking the first time a living biomarker has tracked autopsy-confirmed CTE stages.
  • Signal Velocity: 28 score across 8 independent media sources and 8 indexed articles.
Schematic illustration of the blood-based Raman spectroscopic diagnostic test for ME-CFS and MS.jpg
Illustrative image: Authors of the study: Jiabao Xu, Tiffany Lodge, Caroline Kingdon, James W. L. Strong, John Maclennan, Eliana Lacerda, Slawomir Kujawski, Pawel Zalewski, Wei E. Huang, Karl J. Morten · CC BY 4.0

What happened

For the first time, researchers have shown that a single blood protein can separate advanced chronic traumatic encephalopathy from early-stage or absent disease in people who later underwent brain autopsy. The study, published today in JAMA, analyzed plasma from 21 former American football players — 12 professionals, seven college athletes, and two high-school players — whose blood was drawn during life and whose brains were donated to the Boston University CTE Center. Eighteen donors had CTE at autopsy; 16 of those reached high McKee stages 3 or 4. Concentrations of endogenously cleaved microtubule-binding region tau, or eMTBR-tau, were significantly elevated only in the high-stage group. Donors with low-stage CTE or no CTE showed levels indistinguishable from each other, and a second Alzheimer's marker, p-tau217, rose only when Alzheimer's pathology co-existed.

The finding matters because CTE has until now been a post-mortem diagnosis, blocking clinical trials and leaving families without answers during life. Michael Alosco, co-director of clinical research at the BU CTE Center, called the result a "game changer" but stressed the discovery-phase caveats: 21 participants, no low-stage CTE signal, and a cohort limited to football players. Nicholas Ashton of Banner Health, co-senior author, compared the trajectory to Alzheimer's, where blood p-tau217 assays are now FDA-cleared and used to enroll prevention trials. If eMTBR-tau validates in larger, more diverse cohorts — including women, military veterans, and athletes from non-helmet sports — it could finally let neurologists identify who to treat and measure whether a drug slows tau accumulation.

One donor, Ron "Bogie" Edwards, played in the Canadian and Continental football leagues and tried out for the Denver Broncos. He died at 79 after years of progressive forgetfulness, getting lost, and repeating stories; autopsy confirmed high-stage CTE. His son Rogue said learning his father's blood sample helped prove the biomarker "is everything my dad wanted." That human detail underscores a practical tension: the test currently detects only advanced pathology, the stage when symptoms are already obvious. Whether it can catch CTE early enough for disease-modifying therapy remains the central unanswered question.

Boston University's brain bank has now examined more than 600 donors; a study released this fall found CTE in nearly 75 percent of former NFL players who died between 2008 and 2023. The new blood work used the largest paired ante-mortem plasma and post-mortem tissue set yet assembled, but the authors caution that representation of low-stage CTE, females, and non-football exposures is minimal. Next steps include multi-site validation, assay standardization, and longitudinal sampling to see if eMTBR-tau rises before cognitive decline. Until then, the test stays in the lab — promising, but not yet a clinical tool.

Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 46m ago.

Who reported it (8)

Questions people are asking

Can I ask my doctor for this blood test today?

No. The assay remains a research tool validated in only 21 football players; it has not been FDA-reviewed, standardized for clinical labs, or tested in diverse populations.

Does the test detect early CTE before symptoms start?

Not in this study. Blood eMTBR-tau was elevated only in donors with high-stage (McKee 3-4) CTE; levels in low-stage (1-2) CTE were indistinguishable from donors without CTE.

How is this different from Alzheimer's blood tests already on the market?

The study measured two markers: eMTBR-tau, which rose with high-stage CTE, and p-tau217, which rose only when Alzheimer's pathology was also present. This dual-marker pattern could eventually help clinicians distinguish the two diseases in living patients.

Momentum

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📊 TREND VELOCITY PULSE

Will this trend continue gaining momentum or fade within 24 hours?

Cast your anonymous vote to register reader sentiment on news cycle velocity.

Related visual coverage

Automatically selected only when the subject entities match this story. Embeds remain hosted by their original platforms.

Boston researchers say new blood test could help detect CTE in living patients

YouTube · Boston 25 News

Topics

From around our network

Related trends

◼ Archived Science 🔮 fades ✓

What happens to your brain in space?

Recent studies investigate how space travel affects the human brain and sensory processing during long-term orbital missions.

4 sources 4 articles v 2 133d ago
◼ Archived Sports 🔮 holds ✓

Marshawn Kneeland had stage 1 CTE

Former Cowboys player Marshawn Kneeland’s posthumous CTE diagnosis sparks renewed focus on brain injuries in football

16 sources 17 articles v 17 134d ago